Antisense Oligonucleotides: Rising Stars in Eliminating RNA Toxicity in Myotonic Dystrophy

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2012 Dec 21

PMID 23252746

Citations 21

Authors

Zhihua Gao

Thomas A Cooper

Affiliations

Soon will be listed here.

Abstract

Myotonic dystrophy (DM) is a dominantly inherited, multisystemic disease caused by expanded CTG (type 1, DM1) or CCTG (type 2, DM2) repeats in untranslated regions of the mutated genes. Pathogenesis results from expression of RNAs from the mutated alleles that are toxic because of the expanded CUG or CCUG repeats. Increased understanding of the repeat-containing RNA (C/CUG(exp) RNA)-induced toxicity has led to the development of multiple strategies targeting the toxic RNA. Among these approaches, antisense oligonucleotides (ASOs) have demonstrated high potency in reversing the RNA toxicity in both cultured DM1 cells and DM1 animal models, thus offering great promise for the potential treatment of DM1. ASO targeting approaches will also provide avenues for the treatment of other repeat RNA-mediated diseases.

Citing Articles

Functions of the Muscleblind-like protein family and their role in disease.

Zhou H, Xu J, Pan L Cell Commun Signal. 2025; 23(1):97.

PMID: 39966885 PMC: 11837677. DOI: 10.1186/s12964-025-02102-5.

Disorders: Basics of Biology and Therapeutics in Development.

Gillett D, Tigro H, Wang Y, Suo Z Cells. 2025; 13(24.

PMID: 39768191 PMC: 11674747. DOI: 10.3390/cells13242100.

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions.

Murphy A, Wilton S, Aung-Htut M, McIntosh C Front Mol Neurosci. 2024; 17:1391564.

PMID: 39114642 PMC: 11303307. DOI: 10.3389/fnmol.2024.1391564.

Resistance Exercise Training Rescues Mitochondrial Dysfunction in Skeletal Muscle of Patients with Myotonic Dystrophy Type 1.

Di Leo V, Lawless C, Roussel M, Gomes T, Gorman G, Russell O J Neuromuscul Dis. 2023; 10(6):1111-1126.

PMID: 37638448 PMC: 10657683. DOI: 10.3233/JND-230099.

The role of sleep in neuromuscular disorders.

Angelini C, Ansevin C, Siciliano G Front Neurol. 2023; 14:1195302.

PMID: 37456652 PMC: 10339827. DOI: 10.3389/fneur.2023.1195302.

References

Suenaga K, Lee K, Nakamori M, Tatsumi Y, Takahashi M, Fujimura H . Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain. PLoS One. 2012; 7(3):e33218. PMC: 3302840. DOI: 10.1371/journal.pone.0033218. View

Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D . Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000; 289(5485):1769-73. DOI: 10.1126/science.289.5485.1769. View

Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton C . Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol. 2003; 54(6):760-8. DOI: 10.1002/ana.10763. View

Stevanin G, Fujigasaki H, Lebre A, Camuzat A, Jeannequin C, Dode C . Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain. 2003; 126(Pt 7):1599-603. DOI: 10.1093/brain/awg155. View

Matsuura T, Yamagata T, Burgess D, Rasmussen A, Grewal R, Watase K . Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet. 2000; 26(2):191-4. DOI: 10.1038/79911. View

Ranum L, Day J . Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004; 74(5):793-804. PMC: 1181975. DOI: 10.1086/383590. View

Savkur R, Philips A, Cooper T . Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001; 29(1):40-7. DOI: 10.1038/ng704. View

Yin H, Saleh A, Betts C, Camelliti P, Seow Y, Ashraf S . Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther. 2011; 19(7):1295-303. PMC: 3128823. DOI: 10.1038/mt.2011.79. View

10.

Wang G, Kuyumcu-Martinez M, Sarma S, Mathur N, Wehrens X, Cooper T . PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009; 119(12):3797-806. PMC: 2786786. DOI: 10.1172/JCI37976. View

11.

Ward A, Rimer M, Killian J, Dowling J, Cooper T . CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010; 19(18):3614-22. PMC: 2928132. DOI: 10.1093/hmg/ddq277. View

12.

Kim D, Langlois M, Lee K, Riggs A, Puymirat J, Rossi J . HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res. 2005; 33(12):3866-74. PMC: 1176012. DOI: 10.1093/nar/gki698. View

13.

Orengo J, Chambon P, Metzger D, Mosier D, Snipes G, Cooper T . Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2008; 105(7):2646-51. PMC: 2268190. DOI: 10.1073/pnas.0708519105. View

14.

van Deutekom J, Janson A, Ginjaar I, Frankhuizen W, Aartsma-Rus A, Bremmer-Bout M . Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26):2677-86. DOI: 10.1056/NEJMoa073108. View

15.

Weber Y, Roebling R, Kassubek J, Hoffmann S, Rosenbohm A, Wolf M . Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology. 2010; 74(14):1108-17. DOI: 10.1212/WNL.0b013e3181d8c35f. View

16.

Timchenko N, Cai Z, Welm A, Reddy S, Ashizawa T, Timchenko L . RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2000; 276(11):7820-6. DOI: 10.1074/jbc.M005960200. View

17.

Pushechnikov A, Lee M, Childs-Disney J, Sobczak K, French J, Thornton C . Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc. 2009; 131(28):9767-79. PMC: 2731475. DOI: 10.1021/ja9020149. View

18.

Jansen G, Groenen P, Bachner D, Jap P, Coerwinkel M, Oerlemans F . Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet. 1996; 13(3):316-24. DOI: 10.1038/ng0796-316. View

19.

Novelli G, Gennarelli M, Zelano G, Pizzuti A, Fattorini C, Caskey C . Failure in detecting mRNA transcripts from the mutated allele in myotonic dystrophy muscle. Biochem Mol Biol Int. 1993; 29(2):291-7. View

20.

Mahadevan M, Yadava R, Yu Q, Balijepalli S, Frenzel-McCardell C, Bourne T . Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet. 2006; 38(9):1066-70. PMC: 2909745. DOI: 10.1038/ng1857. View